Oculis to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical firm focused on eye care, announced its participation in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference.
Riad Sherif, M.D., CEO of Oculis, will join a panel discussion titled 'Derisked Late-stage Candidates for Retinal Disorders' on August 15, 2024, at 11:00 am ET.
Additionally, Dr. Sherif will give a virtual company presentation available on-demand starting August 15, 2024, at 7:00 am ET.
Access to the presentation and panel discussion will be available through the Oculis website under the Events & Presentation page in the Investors & Media section.
Oculis Holding AG (Nasdaq: OCS), un'azienda biofarmaceutica globale focalizzata sulla cura degli occhi, ha annunciato la sua partecipazione alla 4a Conferenza Virtuale Annuale di Oftalmologia H.C. Wainwright.
Riad Sherif, M.D., CEO di Oculis, parteciperà a una discussione in panel intitolata 'Candidati tardivi a basso rischio per disturbi retinici' il 15 agosto 2024 alle 11:00 ET.
Inoltre, il Dr. Sherif terrà una presentazione virtuale dell'azienda disponibile on-demand a partire dal 15 agosto 2024 alle 7:00 ET.
L'accesso alla presentazione e alla discussione in panel sarà disponibile sul sito web di Oculis nella pagina Eventi & Presentazioni nella sezione Investitori & Media.
Oculis Holding AG (Nasdaq: OCS), una empresa biofarmacéutica global centrada en el cuidado ocular, anunció su participación en la 4ª Conferencia Virtual Anual de Oftalmología H.C. Wainwright.
Riad Sherif, M.D., CEO de Oculis, se unirá a una discusión en panel titulada 'Candidatos en etapas avanzadas de bajo riesgo para trastornos retinianos' el 15 de agosto de 2024 a las 11:00 am ET.
Además, el Dr. Sherif realizará una presentación virtual de la empresa disponible bajo demanda a partir del 15 de agosto de 2024 a las 7:00 am ET.
El acceso a la presentación y la discusión en panel estará disponible a través del sitio web de Oculis en la página Eventos & Presentaciones en la sección Inversores & Medios.
Oculis Holding AG (Nasdaq: OCS), 안과 치료에 중점을 둔 글로벌 바이오제약 회사로, H.C. Wainwright 제4회 연례 안과 가상 회의에 참가한다고 발표했습니다.
Riad Sherif, M.D.는 '망막 질환을 위한 낮은 위험의 후기 단계 후보'라는 패널 토론에 참석할 예정이며, 2024년 8월 15일 오전 11시 ET에 진행됩니다.
또한, Sherif 박사는 2024년 8월 15일 오전 7시 ET부터 주문형으로 제공되는 회사 발표를 진행할 것입니다.
발표 및 패널 토론에 대한 접근은 Oculis 웹사이트의 이벤트 및 발표 페이지 안의 투자자 및 미디어 섹션을 통해 가능합니다.
Oculis Holding AG (Nasdaq: OCS), une société biopharmaceutique mondiale spécialisée dans le soin des yeux, a annoncé sa participation à la 4ème Conférence Virtuelle Annuelle d'Ophthalmologie H.C. Wainwright.
Riad Sherif, M.D., PDG d'Oculis, participera à une discussion en panel intitulée 'Candidats avancés à risque réduit pour les troubles rétiniens' le 15 août 2024 à 11h00 ET.
De plus, Dr. Sherif fera une présentation virtuelle de l'entreprise, disponible à la demande à partir du 15 août 2024 à 7h00 ET.
L'accès à la présentation et à la discussion en panel sera disponible sur le site web d'Oculis dans la page Événements & Présentations dans la section Investisseurs & Médias.
Oculis Holding AG (Nasdaq: OCS), ein globales biopharmazeutisches Unternehmen, das sich auf Augenpflege spezialisiert hat, gab seine Teilnahme an der 4. jährlichen virtuellen Ophthalmologiekonferenz von H.C. Wainwright bekannt.
Riad Sherif, M.D., CEO von Oculis, wird an einer Podiumsdiskussion mit dem Titel 'Risikofreie Kandidaten in späten Stadien für Netzhauterkrankungen' am 15. August 2024 um 11:00 Uhr ET teilnehmen.
Darüber hinaus wird Dr. Sherif eine virtuelle Unternehmenspräsentation halten, die ab dem 15. August 2024 um 7:00 Uhr ET auf Abruf verfügbar ist.
Der Zugang zur Präsentation und zur Podiumsdiskussion ist über die Website von Oculis unter der Seite Veranstaltungen & Präsentationen im Abschnitt Investoren & Medien verfügbar.
- None.
- None.
ZUG, Switzerland, July 30, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Oculis’ management will be participating at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference.
Riad Sherif, M.D., Chief Executive Officer of Oculis, will participate in a panel discussion titled “Derisked Late-stage Candidates for Retinal Disorders” on August 15, 2024, at 11:00 am ET. Dr. Sherif will also deliver a virtual company presentation which will be available on-demand, on August 15, 2024, at 7:00 am ET.
Links to access the company presentation and panel discussion, when available, will be posted to the Oculis website on the Events & Presentation page under the Investors & Media section.
About Oculis
Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) purposefully driven to save sight and improve eye care. Oculis’ highly differentiated pipeline comprises multiple innovative product candidates in development. It includes OCS-01, a topical eye drop candidate for diabetic macular edema (DME) and for the treatment of inflammation and pain following cataract surgery; licaminlimab (OCS-02), a topical biologic anti-TNFα eye drop candidate for dry eye disease (DED) and for non-infectious anterior uveitis; and OCS-05, a neuroprotective candidate for acute optic neuritis (AON). Headquartered in Switzerland and with operations in the U.S. and Iceland, Oculis’ goal is to improve the health and quality of life of patients worldwide. The company is led by an experienced management team with a successful track record and is supported by leading international healthcare investors.
For more information, please visit: www.oculis.com
Oculis Contact
Ms. Sylvia Cheung, CFO
sylvia.cheung@oculis.com
Investor & Media Relations
LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com
1-212-915-2577
FAQ
What event is Oculis (OCS) participating in?
When will Dr. Riad Sherif present at the conference?
Where can I access Oculis' presentation and panel discussion?
What is the focus of Dr. Sherif's panel discussion?
